Vol. 64, No. 7 (2016)
Chem. Pharm. Bull.
835
2,6-Ditosyl-2,3,4,5,6,7-hexahydro-1H-pyrazolo[1′,2′:1,2]- 2.44 (3H, s). 13C-NMR (125MHz, CDCl3) δ: 147.4, 141.0,
[1,2,3]triazolo[4,5-g][1,5]diazonin-9-ium-8-ide (1i) (Method B) 140.7, 130.7, 128.8, 127.4, 127.0, 126.2, 109.9, 107.4, 102.3,
1H-NMR (500MHz, CDCl3) δ: 7.73 (2H, d, J=8.0Hz), 7.68 90.4, 11.3. IR (KBr) cm−1: 3151, 2923, 1471, 1445, 1412, 1393,
(2H, d, J=8.0Hz), 7.54 (1H, d, J=3.0Hz), 7.36–7.34 (5H, m), 1236, 1112, 1034, 1006, 947, 843, 766, 728, 575. HR-MS
6.62 (1H, t, J=3.0Hz), 4.81 (2H, s), 4.34 (2H, s), 3.53–3.51 (ESI) m/z [M+Na]+ Calcd for [C18H15N3Na]+ 296.1164. Found
(2H, m), 3.03 (2H, t, J=6.0Hz), 2.45 (6H, d, J=3.5Hz), 296.1161. UV/Vis (CH2Cl2): λmax (logε)=360 (3.71), 290
1.92–1.88 (2H, m). 13C-NMR (125MHz, CDCl3) δ: 143.7, (4.69) nm. FL (CH2Cl2): λmax=491nm; ΦF=0.40 (reference to
141.7, 130.0, 127.6, 127.0, 108.5, 103.9, 103.2, 102.6, 48.3, 9,10-DPA; excited at 370nm).
48.06, 48.02, 43.4, 29.5, 21.5. IR (KBr) cm−1: 3155, 2925, 2857,
5-Methyl-2-(naphthalen-2-yl)pyrazolo[1,2-a][1,2,3]triazol-8-
1449, 1335, 1160, 548. HR-MS (ESI) m/z [M+Na]+ Calcd for ium-1-ide (4g) (Method A)
[C24H27N5O4S2Na]+ 536.1402. Found 536.1385.
1H-NMR (500MHz, CDCl3) δ: 8.33 (1H, s), 7.97–7.88 (4H,
2-(Methoxycarbonyl)-5-methylpyrazolo[1,2-a][1,2,3]- m), 7.55–7.49 (3H, m), 7.47 (1H, br-s), 6.46 (1H, s), 2.43 (3H,
triazol-8-ium-1-ide (4b) (Method A)
d, J=3.5Hz). 13C-NMR (125MHz, CDCl3) δ: 147.4, 134.5,
1H-NMR (400MHz, CDCl3) δ: 7.46 (1H, d, J=1.0Hz), 7.41 134.2, 129.2, 128.6, 127.44, 127.37, 127.1, 125.04, 125.03124.8,
(1H, dd, J=2.8Hz, 1.0Hz), 6.48 (1H, dd, J=2.6Hz, 0.6Hz), 123.6, 110.0, 108.5, 11.2. IR (KBr) cm−1: 2925. HR-MS (ESI)
3.95 (3H, s), 2.43 (3H, s). 13C-NMR (100MHz, C6D6) δ: m/z [M+H]+ Calcd for [C16H14N3]+ 248.1188. Found 248.1181.
162.4, 140.1, 109.8, 109.0, 102.0, 97.6, 51.5, 10.3. IR (KBr) UV/Vis (CH2Cl2): λmax (logε)=356 (3.88), 291 (4.53) nm. FL
cm−1: 3133, 2949, 1717, 1557, 1516, 1266, 1003. HR-MS (ESI) (CH2Cl2): λmax=485nm; ΦF=0.082 (reference to 9,10-DPA;
m/z [M+Na]+ Calcd for [C8H9N3O2Na]+ 202.0592. Found excited at 360nm).
202.0586. UV/Vis (CH2Cl2): λmax (logε)=354 (3.44) nm. FL
(CH2Cl2): λmax=456nm; ΦF=0.24 (reference to 9,10-DPA; ex- [1′,2′:1,2][1,2,3]triazolo[4,5-g][1,5]diazonin-9-ium-8-ide
cited at 370nm).
2-(4-(Methoxysulfonyl)phenyl)-5-methylpyrazolo[1,2-a]-
[1,2,3]triazol-8-ium-1-ide (4c) (Method B)
12-Methyl-2,6-ditosyl-2,3,4,5,6,7-hexahydro-1H-pyrazolo-
(4i)
(Method B)
1H-NMR (500MHz, CDCl3) δ: 7.84 (2H, d, J=8.3Hz),
7.69 (2H, d, J=8.3Hz), 7.45 (2H, d, J=7.5Hz), 7.37 (2H, d,
1H-NMR (500MHz, CDCl3) δ: 7.96 (2H, d, J=8.8Hz), J=8.3Hz), 6.37 (1H, d, J=1.7Hz), 5.09 (3H, s), 4.26 (2H,
7.94 (2H, d, J=8.8Hz), 7.42 (1H, d, J=2.2Hz), 7.27 (1H, s), s), 3.30–3.26 (2H, m), 2.87–2.83 (2H, m), 2.72 (3H, s), 2.52
6.40 (1H, d, J=2.2Hz), 3.79 (3H, s), 2.44 (3H, s). 13C-NMR (3H, s), 2.48 (3H, s). 13C-NMR (125MHz, C6D6) δ: 143.2,
(125MHz, CDCl3) δ: 145.4, 137.5, 134.0, 128.5, 126.3, 110.7, 138.2, 134.7, 130.2, 129.7, 113.6, 108.1, 102.6, 101.3, 49.6,
108.0, 102.7, 91.5, 56.4, 11.2. HR-MS (ESI) m/z [M+H]+ 48.7, 44.7, 40.3, 30.0, 21.0, 11.2. IR (KBr) cm−1: 2924, 2865,
Calcd for [C13H14N3O3S]+ 292.0756. Found 292.0757. UV/Vis 1335, 1159, 814, 547. HR-MS (ESI) m/z [M+Na]+ Calcd for
(CH2Cl2): λmax (logε)=393 (2.99), 284 (4.08) nm. FL (CH2Cl2): [C25H30N5O4S2Na]+ 528.1739. Found 528.1742.
λmax=558nm; ΦF=0.40 (reference to rhodamine B; excited at
370 nm).
2-(4-(Methoxycarbonyl)phenyl)-5-methylpyrazolo[1,2-a]-
[1,2,3]triazol-8-ium-1-ide (4d) (Method B)
2-(Methoxycarbonyl)-5-phenylpyrazolo[1,2-a][1,2,3]-
triazol-8-ium-1-ide (4k) (Method A)
1H-NMR (400MHz, CDCl3) δ: 8.08(1H, s), 7.59–7.57 (3H,
overlapped), 7.49 (2H, dd, J=8.3Hz, 7.5Hz), 7.30 (1H, t,
1H-NMR (400MHz, C6D6) δ: 8.25 (1H, d, J=8.5Hz), 7.92 J=7.5Hz), 6.99 (1H, d, J=2.5Hz), 3.99 (3H, s). 13C-NMR
(1H, d, J=8.8Hz), 7.05 (1H, d, J=2.5Hz), 6.53 (1H, br s), 5.81 (100MHz, C6D6) δ: 162.0, 140.4, 129.7, 129.3, 126.3, 123.6,
(1H, dd, J=2.8Hz, 0.8Hz), 3.52 (3H, s), 1.76 (3H, s). 13C-NMR 115.5, 108.1, 104.1, 101.1, 51.6. IR (KBr) cm−1: 3151, 2951,
(125MHz, C6D6) δ: 166.4, 146.8, 136.9, 130.3, 128.4, 125.9, 1733, 1522, 1396, 1223, 1008. HR-MS (ESI) m/z [M+H]+
109.2, 107.5, 101.7, 91.2, 51.5, 10.6. HR-MS (ESI) m/z [M+H]+ Calcd for [C13H12N3O2]+ 242.0930. Found 242.0937. UV/
Calcd for [C14H14N3O2]+ 256.1086. Found 256.1095. UV/Vis Vis (CH2Cl2): λmax (logε)=358 (4.03) nm. FL (CH2Cl2):
(CH2Cl2): λmax (logε)=380 (3.50), 288 (4.61) nm. FL (CH2Cl2): λmax=459nm; ΦF=0.086 (reference to 9,10-DPA; excited at
λmax=553nm; ΦF=0.56 (reference to rhodamine B; excited at 370 nm).
420nm).
2-(4-(Methoxysulfonyl)phenyl)-5-phenylpyrazolo[1,2-a]-
2-(2-Cyano-4-(methoxycarbonyl)phenyl)-5-methyl- [1,2,3]triazol-8-ium-1-ide (4l) (Method B)
pyrazolo[1,2-a][1,2,3]triazol-8-ium-1-ide (4e) (Method B)
1H-NMR (500MHz, CDCl3) δ: 8.03 (2H, d, J=8.5Hz),
1H-NMR (400MHz, C6D6) δ: 8.29 (1H, d, J=8.3Hz), 7.98 (2H, d, J=9.0Hz), 7.90 (1H, d, J=1.0Hz), 7.62 (1H,
8.18 (1H, d, J=1.8Hz), 8.00 (1H, dd, J=8.3Hz, 1.8Hz), 7.70 dd, J=11.5Hz, 1.0Hz), 7.61 (1H, d, J=0.5Hz), 7.51 (2H, t,
(1H, d, J=1.0Hz), 6.99 (1H, dd, J=2.5Hz, 1.0Hz), 5.75 (1H, J=7.5Hz), 7.31 (1H, d, J=7.5Hz), 6.92 (1H, d, J=3.0Hz), 3.81
dd, J=2.5Hz, 0.7Hz), 3.41 (3H, s), 1.63 (3H, s). 13C-NMR (3H, s). 13C-NMR (125MHz, CDCl3) δ: 146.0, 137.0, 134.5,
(125MHz, C6D6) δ: 164.8, 143.1, 139.0, 135.6, 133.8, 130.2, 129.6, 129.3, 128.6, 126.6, 126.4, 123.7, 116.0, 107.1, 104.7,
128.9, 119.1, 110.8, 109.5, 108.5, 102.1, 94.1, 52.1, 10.5. HR-MS 94.7, 56.4. IR (KBr) cm−1: 2924, 2851, 1729, 1601, 1362, 1176,
(ESI) m/z [M+Na]+ Calcd for [C15H12N4O2Na]+ 303.0858. 988. HR-MS (ESI) m/z [M+H]+ Calcd for [C18H16N3O3S]+
Found 303.0854. UV/Vis (CH2Cl2): λmax (logε)=436 (3.05), 354.0912. Found 354.0912. UV/Vis (CH2Cl2): λmax (logε)=378
287 (4.23) nm. FL (CH2Cl2): λmax=611nm; ΦF=0.11 (reference (3.74) nm, 345 (4.29) nm, 277 (4.31) nm. FL (CH2Cl2):
to rhodamine B; excited at 420nm).
λmax=554nm; ΦF=0.21 (reference to rhodamine B; excited at
2-([1,1′-Biphenyl]-4-yl)-5-methylpyrazolo[1,2-a][1,2,3]- 400 nm).
triazol-8-ium-1-ide (4f) (Method A)
2-(4-(Methoxycarbonyl)phenyl)-5-phenylpyrazolo[1,2-a]-
1H-NMR (500MHz, CDCl3) δ: 7.86 (2H, d, J=8.5Hz), 7.65 [1,2,3]triazol-8-ium-1-ide (4m) (Method B)
(4H, t, J=8.3Hz), 7.46 (2H, brt, J=7.8Hz), 7.42 (1H, brd,
1H-NMR (400MHz, CDCl3) δ: 8.11 (2H, d, J=8.3Hz), 7.90
J=2.5Hz), 7.36 (1H, brt, J=7.3Hz), 6.36 (1H, brd, J=2.0Hz), (2H, d, J=8.6Hz), 7.86 (1H, s), 7.60 (2H, d, J=7.5Hz), 7.58